免疫细胞疗法产业发展态势和发展建议

doi:10.13523/j.cb.20180514

中国生物工程杂志

2018, Vol. 38

Issue (5): 104-111 DOI: 10.13523/j.cb.20180514

行业分析

免疫细胞疗法产业发展态势和发展建议

苏燕¹,许丽¹,王力为²,王玥¹,徐萍^1,^*(

)

1 中国科学院上海生命科学研究院上海 200031
2 中国科学院前沿科学与教育局北京 100864

The Development Situation and Suggestions of mmune Cell Therapy Industry

Yan SU¹,Li XU¹,Li-wei WANG²,Yue WANG¹,Ping XU^1,^*(

)

1 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
2 Bureau of Frontier Sciences and Education, Chinese Academy of Sciences, Beijing 100864, China

全文: PDF(851 KB) HTML

摘要：

免疫疗法已被成功应用于多种肿瘤的治疗,显著提高患者的生存质量。免疫细胞疗法是当前免疫疗法研发的重点方向之一。免疫细胞疗法发展历经了由非特异性免疫到无差别化特异性免疫,再到差别化特异性免疫的发展阶段。免疫细胞疗法已有多个产品获批上市,产业体系初步成型,主要包括疗法/药物研发和相关服务/器材供应。通过梳理国内外免疫细胞疗法产业发展态势,分析免疫细胞疗法发展的技术瓶颈,找出我国发展该产业存在的主要问题,并提出发展建议,为我国发展免疫细胞疗法产业提供参考。

关键词： 免疫细胞疗法; 产业态势; 发展瓶颈

Abstract:

Immunotherapy has been successfully applied in the treatment of many kinds of tumors, and significantly improved the quality of life of patients. Immune cell therapy is one of the focus directions in the development of immunotherapy. The development of immune cell therapy has gone through the stage of development of non-specific immunity to non-differentiated specific immunity and to differentiated specific immunity. Several immune cell therapy products have launched, and the industrial system has been preliminarily formed, including treatment/drug development and related services/equipment production. By analyzing the immune cell therapy industry development situation at home and abroad and the technology development bottleneck, main problems of the development of the industry in China are pointed, some suggestions were put forward so as to provide reference for the development of immune cell therapy industry in China.

Key words: Immune cell therapy Industry situation Development bottleneck

收稿日期: 2018-01-23 出版日期: 2018-06-05

ZTFLH:

Q354

通讯作者: 徐萍 E-mail: xuping@sibs.ac.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	苏燕
	许丽
	王力为
	王玥
	徐萍

引用本文:

苏燕,许丽,王力为,王玥,徐萍. 免疫细胞疗法产业发展态势和发展建议[J]. 中国生物工程杂志, 2018, 38(5): 104-111.

Yan SU,Li XU,Li-wei WANG,Yue WANG,Ping XU. The Development Situation and Suggestions of mmune Cell Therapy Industry. China Biotechnology, 2018, 38(5): 104-111.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180514 或 https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I5/104

图1 免疫细胞疗法临床试验数量① ① 数据来源:ClinicalTrials数据库,检索日期2017年12月23日。

Table 1 Global launched immune cell therapy products

图2 免疫细胞疗法产业体系

表2 全球DC治疗临床试验数量排名前5位机构(数据来源:ClinicalTrials数据库,检索日期2017年12月23日)

图3 诺华CAR-T专利技术分析

表3 诺华、朱诺治疗、凯特医药 CAR-T研发管线

表4 国内CAR-T企业组建模式

表5 国内部分企业公开的CAR-T临床数据

[1]	Kantoff P W, Higano C S, Shore N D , et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 2010,363(5):411-422. doi: 10.1016/S0022-5347(11)60154-7
[2]	Barbuto J A, Ensina L F, Neves A R , et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunology Immunotherapy, 2004,53(12):1111-1118. doi: 10.1007/s00262-004-0551-7 pmid: 15185011
[3]	Porter D L, Levine B L, Kalos M , et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 2011,365(8):725-733. doi: 10.1056/NEJMoa1103849 pmid: 21830940
[4]	Kumar C, Kohli S, Chiliveru S , et al. A retrospective analysis comparing APCEDEN (?) dendritic cell immunotherapy with best supportive care in refractory cancer . Immunotherapy, 2017,9(11):889-897. doi: 10.2217/imt-2017-0064 pmid: 28838282
[5]	付贤 . 树突状细胞在去势抵抗前列腺癌免疫治疗中的研究进展. 国际泌尿系统杂志, 2014,34(4):559-562. doi: 10.3760/cma.j.issn.1673-4416.2014.04.028
	Fu X . Advances in research on dendritic cells in castration-resistant prostate cancer immunotherepy. International Journal of Urology and Nephrology, 2014,34(4):559-562. doi: 10.3760/cma.j.issn.1673-4416.2014.04.028
[6]	Harris D T, Kranz D M . Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends in Pharmacological Sciences, 2016,37(3):220-230. doi: 10.1016/j.tips.2015.11.004 pmid: 26705086
[7]	陆虹旻, 李林凤, 高建新 . 基于树突细胞的肿瘤疫苗研究进展. 胃肠病学, 2016,21(5):257-262.
	Lu H M, Li L F, Gao J X . Advances in research on dendritic cell-based tumor vaccine. Chinese Journal of Gastroenterology, 2016,21(5):257-262.
[8]	何永跃 . 胶质瘤免疫治疗与血脑屏障. 国际神经病学神经外科学杂志, 2017,44(1):68-70. doi: 10.16636/j.cnki.jinn.2017.01.016
	He Y Y . Glioma immunotherapy and blood-brain barrier. Journal of International Neurology and Neurosurgery, 2017,44(1):68-70. doi: 10.16636/j.cnki.jinn.2017.01.016
[9]	Kershaw M H, Westwood J A, Parker L L , et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research, 2006,12(20):6106-6115. doi: 10.1158/1078-0432.CCR-06-1183 pmid: 17062687
[10]	Park J R, Digiusto D L, Slovak M , et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with Neuroblastoma. Molecular Therapy, 2007,15(4):825-833. doi: 10.1038/sj.mt.6300104 pmid: 17299405

[1]	杨春艳,王磊,穆登彩,李芳芳,沈昊,郑尚永. 基因编辑技术在疾病治疗中的研究进展 ^*[J]. 中国生物工程杂志, 2019, 39(11): 87-95.
[2]	汪凌,陈新. 肿瘤精准医学知识数据库的设计与构建[J]. 中国生物工程杂志, 2018, 38(5): 40-46.

Viewed

Full text

Abstract

Cited

Shared

Discussed